Search research articles
Contact Us
Filters
Showing results (131-140 of 278) with videos related to
Page
of 28
Sort By:
Blood
|
May 16, 1998
Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice: evidence for the involvement of IL-2 in myelopoiesis
T Reya, N V Contractor, M S Couzens, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 1, 2006
Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders
Mouna El-Salem, Puthiyaveettil N Raghunath, Michal Marzec, et al.
Czasopismo Stomatologiczne
|
January 1, 1986
[The condition of the periodontium, oral hygiene and oral mucosa in workers exposed to harmful factors in the work environment]
A Magas, M Borysewicz-Lewicka, A Wasik, et al.
The American Journal of Pathology
|
July 18, 2009
Activation of mTORC1 signaling pathway in AIDS-related lymphomas
Mouna El-Salem, Puthiyaveettil N Raghunath, Michal Marzec, et al.
The Journal of Experimental Medicine
|
June 24, 1998
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant
P Salomoni, M A Wasik, R F Riedel, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 5, 2006
Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities
Seung-Hee Jo, Chunyan Yang, Qi Miao, et al.
Leukemia
|
October 6, 2000
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines
M Majka, T Rozmyslowicz, M Honczarenko, et al.
Transplantation
|
June 5, 2003
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses
Miroslaw Majewski, Magdalena Korecka, Joanne Joergensen, et al.
Leukemia & Lymphoma
|
June 24, 2008
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma
Elisabetta Capriotti, Eric C Vonderheid, Christopher J Thoburn, et al.
Human Pathology
|
July 1, 1996
Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2
M A Wasik, R Sackstein, D Novick, et al.
Page
of 28
Search research articles
Search
Showing results (131-140 of 278) with videos related to
Sort By:
Page
of 28
Blood
|
May 16, 1998
Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice: evidence for the involvement of IL-2 in myelopoiesis
T Reya, N V Contractor, M S Couzens, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 1, 2006
Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders
Mouna El-Salem, Puthiyaveettil N Raghunath, Michal Marzec, et al.
Czasopismo Stomatologiczne
|
January 1, 1986
[The condition of the periodontium, oral hygiene and oral mucosa in workers exposed to harmful factors in the work environment]
A Magas, M Borysewicz-Lewicka, A Wasik, et al.
The American Journal of Pathology
|
July 18, 2009
Activation of mTORC1 signaling pathway in AIDS-related lymphomas
Mouna El-Salem, Puthiyaveettil N Raghunath, Michal Marzec, et al.
The Journal of Experimental Medicine
|
June 24, 1998
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant
P Salomoni, M A Wasik, R F Riedel, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 5, 2006
Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities
Seung-Hee Jo, Chunyan Yang, Qi Miao, et al.
Leukemia
|
October 6, 2000
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines
M Majka, T Rozmyslowicz, M Honczarenko, et al.
Transplantation
|
June 5, 2003
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses
Miroslaw Majewski, Magdalena Korecka, Joanne Joergensen, et al.
Leukemia & Lymphoma
|
June 24, 2008
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma
Elisabetta Capriotti, Eric C Vonderheid, Christopher J Thoburn, et al.
Human Pathology
|
July 1, 1996
Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2
M A Wasik, R Sackstein, D Novick, et al.
Page
of 28